Document is current
Any future updates will be listed below
-
Authors
Mu, Wei https://orcid.org/0000-0001-7970-8666
Jiang, Lei
Zhang, JianYuan https://orcid.org/0000-0002-6400-2051
Shi, Yu
Gray, Jhanelle E.
Tunali, Ilke
Gao, Chao
Sun, Yingying
Tian, Jie https://orcid.org/0000-0003-0498-0432
Zhao, Xinming https://orcid.org/0000-0002-7060-2643
Sun, Xilin https://orcid.org/0000-0001-7464-5117
Gillies, Robert J. https://orcid.org/0000-0002-8888-7747
Schabath, Matthew B. https://orcid.org/0000-0003-3241-3216
- License Information
-
More Information
Article History
Received: 20 March 2020
Accepted: 14 September 2020
First Online: 16 October 2020
Competing interests
: R.J.G. declared a potential conflict with HealthMyne, Inc (Investor (major), Board of Advisors (uncompensated)). J.E.G. reports receiving commercial research grants from AstraZeneca, Merck, Array, Epic Sciences, Genentech, Bristol-Myers Squibb, BI, Trovagene, and Novartis, and is a consultant/advisory board member for AstraZeneca, Janssen, Genentech, Eli Lilly, Celgene, and Takeda, and other remuneration from Genentech, AstraZeneca, Merck, and Lilly/Genenech. The remaining authors declare no competing interests.
